The role of WR-2721 in radiotherapy and/or chemotherapy

This report summarizes the present status of the proposed use of WR-2721 (S-2-(3-aminopropylamino)-ethylphosphorothioic acid) acid) in radiotherapy and/or chemotherapy. This drug selectively concentrates in normal tissues, both in vivo and in vitro, but is passively absorbed by virtually all of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer clinical trials 1980, Vol.3 (3), p.211
Hauptverfasser:	Yuhas, J M, Spellman, J M, Culo, F
Format:	Artikel
Sprache:	eng
Schlagworte:	Alkylating Agents - therapeutic use Amifostine - metabolism Amifostine - therapeutic use Animals Breast Neoplasms - metabolism Cyclophosphamide - therapeutic use Humans In Vitro Techniques Mechlorethamine - therapeutic use Melphalan - therapeutic use Mice Mice, Inbred BALB C Neoplasms, Experimental - drug therapy Neoplasms, Experimental - metabolism Neoplasms, Experimental - radiotherapy Organothiophosphorus Compounds - therapeutic use Platinum - therapeutic use Rabbits Radiation-Protective Agents Rats Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This report summarizes the present status of the proposed use of WR-2721 (S-2-(3-aminopropylamino)-ethylphosphorothioic acid) acid) in radiotherapy and/or chemotherapy. This drug selectively concentrates in normal tissues, both in vivo and in vitro, but is passively absorbed by virtually all of the solid tumors which have been studied. In vivo this drug can increase the resistance to radiation or alkylating agents (nitrogen mustard, cis-platinum, cyclophosphamide, and L-phenylalamine mustard) by factors of up to 3, while leaving the solid tumors to suffer the full effects of either treatment.
ISSN:	0190-1206